The influence of generator eluate in radiolabeling PSMA-11 kit with 68Ga
DOI:
https://doi.org/10.15392/bjrs.v9i1A.1541Keywords:
prostate cancer, radiolabeling, radiopharmacyAbstract
Gaining prominence in clinical practice, the 68Ga, positron emitter radionuclide easily obtained by 68Ge/68Ga generator elution, has shown potential and excellent quality on radiolabeling of peptide for use in positron emission tomography (PET), in particular urea-based inhibitor peptides, directed to the prostate-specific membrane receptor (PSMA). Previous studies with the PSMA linked to the chelator HBED-CC (PSMA-11) radiolabeled with 68Ga showed high contrast PET/CT images to evaluate recurrence and metastasis of prostate cancer, becoming an important imaging agent in the clinical routine. This work intended to evaluate the influence of the quality of the 68Ge/68Ga generator eluate in direct labelling of PSMA-11 with 68Ga, assisting in the development of kit for prompt radiolabeling. It was evaluated the 68GaCl3 eluate from 68Ge/68Ga non-GMP generator (manufacturer A) and 68Ge/68Ga GMP generator (manufacturer B), both commercially available. To evaluate the influence of the 68Ga eluate on radiochemical yield of the preparations, the radiochemical purity was determined by thin layer chromatography and HPLC. The radiolabeling with non-GMP generator eluate was made with and without preliminary purification of the 68 gallium chloride eluate, employing cationic purification columns. The results showed higher radiochemical yield with the 68GaCl3 eluate from the 68Ge/68Ga GMP generator, obtaining the radiolabeled product more easily and speed to clinical practice, without preliminary purification, as opposed to the use of non-GMP 68Ge/68Ga generator which required preliminary purification of the 68GaCl3 eluate to promote satisfactory radiochemical purity results.
Downloads
References
BRAY, F.; FERLAY, J.; SOERJOMATARAM, I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018, v. 00, p. 1-31, 2018.
Estimativa 2018: Incidência de câncer no Brasil / Instituto Nacional de Câncer José Alencar Gomes da Silva, INCA, 2017.
PACKER, J.; MAITLAND, N. The molecular and cellular origin of human prostate cancer. Biochimica et Biophysica Acta 1863, p. 1238-1260, 2016.
AFSHAR-OROMIEH, A. et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging, v. 42, p. 197–209, 2015.
MIYAHIRA, A.; et al. Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. The Prostate, 2018, p. 1-15, 2018.
VELIKYAN, I. Prospective of 68Ga-Radiopharmaceutical Development. Theranostics, Volume 4, p.47–80, 2013.
BANERJEE, S. R.; POMPER, M. G. Clinical applications of Gallium-68. Appl Radiat Isot., v. 76, p. 2–13, 2013.
Gallium (68Ga) PSMA 11 injection, European pharmacopoeia, 2018.
Published
Issue
Section
License
Copyright (c) 2021 Brazilian Journal of Radiation Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
How to Cite
